MGB tops up cash pool to wrap up antibiotic phase 2a

MGB tops up cash pool to wrap up antibiotic phase 2a

Source: 
Fierce Biotech
snippet: 

MGB Biopharma has raised money to finish a phase 2a trial of its lead antibiotic MGB-BP-3 in people with Clostridium difficile-associated diarrhea. The small financing positions MGB to generate clinical data and prepare for next steps.